{"id":518746,"date":"2021-07-28T07:03:05","date_gmt":"2021-07-28T11:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/"},"modified":"2021-07-28T07:03:05","modified_gmt":"2021-07-28T11:03:05","slug":"renalytix-appoints-ann-berman-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/","title":{"rendered":"Renalytix Appoints Ann Berman to its Board of Directors"},"content":{"rendered":"

\nBerman serves on the board of Loews Corporation, is a member of the board of trustees of Beth Israel Deaconess, and is a former chief financial officer of Harvard University
\n<\/h2>\n
\n

NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) — Renalytix plc<\/a> (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Ann E. Berman to its board of directors. She will chair the board\u2019s audit committee and serve as member of the nomination committee.<\/p>\n

Ms. Berman currently serves on the board of directors and as a member of the audit committee of Loews Corporation (NYSE: L), a $14.5 billion market capitalization company with subsidiaries that include CNA Financial. In addition, Ms. Berman is a member of the board of trustees of Beth Israel Deaconess Medical Center, where she is the chair of the compliance and risk committees and Immuneering Corporation where she chairs the audit committee.<\/p>\n

\u201cWe are delighted to have a professional of Ann\u2019s capabilities on board as Renalytix enters into a substantial growth phase,\u201d said Christopher Mills, interim chairman, Renalytix. \u201cHer leadership and operational experience will be invaluable to helping us drive shareholder value.\u201d<\/p>\n

Ms. Berman commented, \u201cRenalytix is doing important and exciting work in improving the care and treatment of kidney disease. I am very pleased to contribute my expertise to advancing the company and supporting its goals.\u201d<\/p>\n

Preceding her retirement in 2009, Ms. Berman served as chief financial officer of Harvard University. During her tenure at Harvard, Ms. Berman was responsible for financial strategy, policy and planning, financial reporting and operations, treasury and risk management, and various audit functions. As part of her role, she served on the board of Harvard Management Company, the investment management firm for Harvard University\u2019s endowment. Before joining Harvard University, from 1978 to 1985, Ms. Berman was a partner with Richard A. Eisner & Co., an accounting firm. She began her career in finance at Price Waterhouse & Co.<\/p>\n

Ms. Berman is a certified public accountant who is qualified as a financial expert for audit committee leadership, with extensive experience overseeing audit-related matters, enterprise risk management, internal audit, cybersecurity, and compliance. Ms. Berman earned a B.A. in French language and literature at Cornell University, Phi Beta Kappa, and an M.B.A. with a concentration in accounting from the University of Pennsylvania\u2019s Wharton School of Business.<\/p>\n

\n About Renalytix<\/strong>
\n
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company\u2019s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.<\/p>\n

\n Forward Looking Statements<\/strong>
\n
Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully distributed and marketed, our expectations regarding reimbursement decisions, our plans for expansion of our business and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cseeks,\u201d and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the \u201cRisk Factors\u201d section of our annual report on Form 20-F filed with the SEC on October 28, 2020, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n

\n Media Contacts:<\/strong>
\n
United States:
Jennifer Moritz
Zer0 to 5ive for Renalytix
(917) 748-4006
jmoritz@0to5.com<\/p>\n

Outside of the United States:
Walbrook PR Limited\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Paul McManus \/ Lianne Cawthorne
Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 \/ 07584 391 303\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

AIM Rule regulatory disclosures<\/p>\n

In accordance with Schedule 2(g) of the AIM Rules, Ann Elyse Berman (aged 69) holds or has held in the past 5 years the following directorships and partnerships:<\/p>\n\n\n\n\n\n
\n Current<\/strong>\n <\/td>\n\n Past 5 years<\/strong>\n <\/td>\n<\/tr>\n
Loews Corporation<\/td>\nCantel Medical Corporation<\/td>\n<\/tr>\n
Beth Israel Deaconess Medical Center<\/td>\nEaton Vance Corporation<\/td>\n<\/tr>\n
Immuneering Corporation<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Save for the disclosures above, there are no further disclosures to be made in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Berman serves on the board of Loews Corporation, is a member of the board of trustees of Beth Israel Deaconess, and is a former chief financial officer of Harvard University NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Ann E. Berman to its board of directors. She will chair the board\u2019s audit committee and serve as member of the nomination committee. Ms. Berman currently serves on the board of directors and as a member of the audit committee of Loews Corporation (NYSE: L), a $14.5 billion market capitalization company with subsidiaries that include CNA Financial. In addition, Ms. Berman is a member of the board … <\/p>\n

Continue reading “Renalytix Appoints Ann Berman to its Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-518746","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRenalytix Appoints Ann Berman to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Renalytix Appoints Ann Berman to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Berman serves on the board of Loews Corporation, is a member of the board of trustees of Beth Israel Deaconess, and is a former chief financial officer of Harvard University NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Ann E. Berman to its board of directors. She will chair the board\u2019s audit committee and serve as member of the nomination committee. Ms. Berman currently serves on the board of directors and as a member of the audit committee of Loews Corporation (NYSE: L), a $14.5 billion market capitalization company with subsidiaries that include CNA Financial. In addition, Ms. Berman is a member of the board … Continue reading "Renalytix Appoints Ann Berman to its Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-28T11:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Renalytix Appoints Ann Berman to its Board of Directors\",\"datePublished\":\"2021-07-28T11:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/\"},\"wordCount\":912,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/\",\"name\":\"Renalytix Appoints Ann Berman to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=\",\"datePublished\":\"2021-07-28T11:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renalytix-appoints-ann-berman-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Renalytix Appoints Ann Berman to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Renalytix Appoints Ann Berman to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Renalytix Appoints Ann Berman to its Board of Directors - Market Newsdesk","og_description":"Berman serves on the board of Loews Corporation, is a member of the board of trustees of Beth Israel Deaconess, and is a former chief financial officer of Harvard University NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Ann E. Berman to its board of directors. She will chair the board\u2019s audit committee and serve as member of the nomination committee. Ms. Berman currently serves on the board of directors and as a member of the audit committee of Loews Corporation (NYSE: L), a $14.5 billion market capitalization company with subsidiaries that include CNA Financial. In addition, Ms. Berman is a member of the board … Continue reading \"Renalytix Appoints Ann Berman to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-28T11:03:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Renalytix Appoints Ann Berman to its Board of Directors","datePublished":"2021-07-28T11:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/"},"wordCount":912,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/","name":"Renalytix Appoints Ann Berman to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=","datePublished":"2021-07-28T11:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4Nzk1MSM0MzE3NzkyIzIyMDEwMjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renalytix-appoints-ann-berman-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Renalytix Appoints Ann Berman to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/518746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=518746"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/518746\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=518746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=518746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=518746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}